retatrutide weight loss study Lilly's triple agonist, retatrutide, delivered powerful in pivotal Phase 3 obesity trial Retatrutide Results: 28.3% Weight Loss

It slows food digestion in the stomach

Weight-loss outcomes supported by peer-reviewed clinical data Naturally helps curb appetite and minimize unnecessary snacking Encourages a more efficient metabolism and consistent daily energy Supports healthier insulin function and more stable blood-sugar patterns Promotes lasting fullness to help reduce overeating GLP-1s work with your body's natural biology to support meaningful, sustainable weight loss

Compounded injectable semaglutide This is the same active ingredient found in Ozempic and Wegovy, produced by a compounding pharmacy rather than Novo Nordisk

Detailed conversion scenarios The following are detailed conversion scenarios of GLP-1 medications: Switching from liraglutide (Victoza/Saxenda) to semaglutide (Ozempic/Wegovy) Liraglutide is a daily injection, while semaglutide is administered once weekly